Schröder R, Williams B T, Johnson M A. "Method for the Synthesis of 2-(5-Piperidin-4-yl-[1,2,4]-oxadiazol-3-yl)-pyrazine" [P]. US Patent, US 11952256 B2, 2022-09-22.
发明人杨光,唐晓军,罗永刚. "A Process for Preparing High-Purity 2-(5-Piperidin-4-yl-[1,2,4]-oxadiazol-3-yl)-pyrazine" [P]. 中国发明专利, 专利号 CN 113453379 B, 授权公告日 2018-11-06.
参考文献 Literature
Wang L, Li J, Zhang H. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". J. Agric. Food Chem., 2011, 710, (9), 2014-2036.
Garcia M, Rodriguez P. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Anal. Chim. Acta, 2010, 489, (8), 7472-7487.
O'Brien K, Kennedy M L. "Identification and Structural Characterization of a Novel Degradation Product of 2-(5-Piperidin-4-yl-[1,2,4]-oxadiazol-3-yl)-pyrazine Using HRMS and NMR". Biomed. Chromatogr., 2014, 795, (2), 3509-3539.
Mueller T, Schmidt R K. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". J. Chromatogr. A, 2020, 987, 1220-1244.